# 1 Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows

# 2 improvement of recovery in COVID-19 patients in an interim analysis of a

- 3 clinical trial 4 Olha Holubovska<sup>1,11</sup>, Denisa Bojkova<sup>2,11</sup>, Stefano Elli<sup>3,11</sup>, Marco Bechtel<sup>2</sup>, David Boltz<sup>4</sup>, Miguel Muzzio<sup>4</sup>, Xinjian Peng<sup>4</sup>, Frederico Sala<sup>3</sup>, Cesare Cosentino<sup>3</sup>, Alla 5 6 Mironenko<sup>5</sup>, Jens Milde<sup>6</sup>, Yuriy Lebed<sup>7</sup>, Holger Stammer<sup>6</sup>, Andrew Goy<sup>8</sup>, Marco 7 Guerrini<sup>3</sup>, Lutz Mueller<sup>9\*</sup>, Jindrich Cinatl<sup>2\*</sup>, Victor Margitich<sup>8\*</sup>, and Aartjan J. W. te 8 Velthuis<sup>10,11\*</sup> 9 10 <sup>1</sup>O.O. Bogomolets National Medical University, T. Shevchenko blvd., 13, Kyiv, 11 12 Ukraine 13 <sup>2</sup>Institute of Medical Virology, University Hospital Frankfurt, Goethe University, 14 Frankfurt am Main. Germany <sup>3</sup>Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 15 81, 20133 Milano, Italy 16 <sup>4</sup>IIT Research institute, 10 W 35th St, Chicago, IL 60616, United States 17 18 <sup>5</sup>L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS 19 of Ukraine, Department of respiratory and other viral infections, Amosova str 5a, 20 03083, Kyiv, Ukraine <sup>6</sup>Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany 21 <sup>7</sup>Pharmaxi LLC, Filatova Str., 10A, office 3/20, 01042, Kyiv, Ukraine 22 23 <sup>8</sup>Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine <sup>9</sup>Dr. Regenold GmbH, Zöllinplatz 4, D-79410 Badenweiler, Germany 24 <sup>10</sup>Division of Virology, Department of Pathology, Addenbrooke's Hospital, University 25 of Cambridge, Hills Road, CB2 2QQ, United Kingdom 26 <sup>11</sup>These authors contributed equally 27 28 29 Corresponding authors. E-mail: ajwt6@cam.ac.uk, cinatl@em.uni-frankfurt.de, 30 lutz.mueller@regenold.com, v.margitich@farmak.ua 31 32 Key words: Covid-19, SARS-CoV-2, molecular dynamics simulation, RNA 33 polymerase, FAV00A, Amizon 34 35
- 36 Phase III clinical trial registered at ClinicalTrials.gov under number NCT04682873.
- 37

#### 38 Abstract

39 Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called 40 Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend 41 on vaccine-induced or naturally acquired protective herd immunity. Until then, 42 antiviral strategies are needed to manage COVID-19, but approved antiviral 43 treatments, such as remdesivir, can only be delivered intravenously. Enisamium 44 (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of 45 influenza A and B viruses in cell culture and clinically approved in countries of the 46 Commonwealth of Independent States. Here we show that enisamium can inhibit 47 SARS-CoV-2 infections in NHBE and Caco-2 cells. In vitro, the previously identified 48 enisamium metabolite VR17-04 directly inhibits the activity of the SARS-CoV-2 RNA 49 polymerase. Docking and molecular dynamics simulations suggest that VR17-04 50 prevents GTP and UTP incorporation. To confirm enisamium's antiviral properties, 51 we conducted a double-blind, randomized, placebo-controlled trial in adult, 52 hospitalized COVID-19 patients, which needed medical care either with or without 53 supplementary oxygen. Patients received either enisamium (500 mg per dose) or 54 placebo for 7 days. A pre-planned interim analysis showed in the subgroup of 55 patients needing supplementary oxygen (n = 77) in the enisamium group a mean 56 recovery time of 11.1 days, compared to 13.9 days for the placebo group (log-rank 57 test; p=0.0259). No significant difference was found for all patients (n = 373) or those 58 only needing medical care (n = 296). These results thus suggest that enisamium is 59 an inhibitor of SARS-CoV-2 RNA synthesis and that enisamium treatment shortens 60 the time to recovery for COVID-19 patients needing oxygen.

61

#### 62 Significance statement

63 SARS-CoV-2 is the causative agent of COVID-19. Although vaccines are now 64 becoming available to prevent SARS-CoV-2 spread, the development of antivirals 65 remains necessary for treating current COVID-19 patients and combating future 66 coronavirus outbreaks. Here, we report that enisamium, which can be administered 67 orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can 68 inhibit the SARS-CoV-2 RNA polymerase in vitro. Moreover, we find that COVID-19 69 patients requiring supplementary oxygen, recover more quickly than patients treated 70 with a placebo. Enisamium may therefore be an accessible treatment for COVID-19 71 patients.

#### 73 Introduction

Severe acute respiratory coronavirus 2 (SARS-CoV-2) is an important human pathogen and the causative agent of COVID-19. Vaccines are available to prevent the spread of SARS-CoV-2, and several antiviral strategies, such as treatment with remdesivir or reconvalescent plasma, have received emergency approval. However, the development of additional strategies remains necessary since vaccine roll-out is slow and current treatments can only be delivered intravenously. A key target for novel drug screening is the RNA polymerase of SARS-CoV-2 (1-4).

81 SARS-CoV-2 is a betacoronavirus and contains a positive-sense, non-82 segmented RNA genome of around 30 kilobases (5, 6). The 5' two-thirds of the viral 83 genome encode two overlapping open reading frames (ORFs), 1a and 1b, which are 84 translated into two large polyproteins by host cell ribosomes. The two polyproteins 85 are cleaved by intrinsic proteolytic activity to produce 16 non-structural proteins 86 (nsps). Nsp12 is the RNA-dependent RNA polymerase that copies and transcribes 87 the SARS-CoV-2 genome (7, 8). Nsp12 requires nsp7 and nsp8 for processivity in 88 vitro (9) and likely other nsps, such as nsp9 and nsp13, for processivity in vivo. The 89 structures of nsp12/7/8 and nsp8/9/12/13 complexes from SARS-CoV and SARS-90 CoV-2 have been solved by cryo-EM (10-12).

91 Remdesivir has been shown to inhibit the SARS-CoV-2 nsp12/7/8 complex 92 and other nucleoside analogue drugs or small molecule inhibitors have been 93 suggested as therapeutic candidates (1-3). One of the drugs highlighted by the 94 World Health Organisation as a candidate therapeutic against SARS-CoV-2 is 95 (4-(benzylcarbamoyl)-1-methylpyridinium) iodide enisamium (laboratory code 96 FAV00A, marketed as Amizon®; Fig. 1A). Enisamium is licensed for use in 11 97 countries and a recent study found that enisamium is hydroxylated in humans and 98 human lung cells to a compound called VR17-04 (Fig. 1A). VR17-04 inhibits the 99 activity of the influenza virus RNA polymerase and reduces viral shedding and 100 improves patient recovery in influenza patients (13).

In this study, we show that enisamium metabolite VR17-04 inhibits the SARS-CoV-2 nsp12/7/8 complex *in vitro*, likely by preventing incorporation of GTP and UTP. We also show that parent compound enisamium inhibits SARS-CoV-2 growth on Caco-2 and NHBE cells. In patients needing medical care and supplementary oxygen COVID-19 (Severity Rating 4 [SR 4] of the modified WHO ordinal scale), enisamium significantly improved the time to recovery compared to a placebo

107 control. These data imply that enisamium is a possible therapeutic option for treating

108 SARS-CoV-2 infection.

109

#### 110 **Results**

#### 111 Enisamium inhibits SARS-CoV-2 infection in cell culture

112 Previous experiments showed that enisamium (Fig. 1A) can efficiently inhibit 113 influenza virus replication in normal human bronchial epithelial (NHBE) cultures and 114 A549 cells, and to a lesser extent in Caco-2 cells (13). Previous experiments have 115 also demonstrated that enisamium is not cytotoxic to these cells (13). To test if 116 enisamium can inhibit pandemic SARS-CoV-2 replication in cell culture, we first 117 incubated Caco-2 cells, a standard cell-line for SARS-CoV-2 infection in vitro, with 118 enisamium iodide or enisamium chloride for 6 hours and subsequently infected the 119 treated cells with SARS-CoV-2. After 48 hours, inhibition of viral infection was 120 assessed by antigen staining for viral nucleoprotein expression and RT-qPCR for 121 viral genome replication. We observed a significant reduction in both viral 122 nucleoprotein expression (Fig. 1B), a reduction in the cytopathic effect of the SARS-123 CoV-2 infection on Caco-2 cells (Fig. 1C), and a 2-log reduction in the number of 124 viral genome copies in the infected cells as a function of the enisamium 125 concentration (Fig. S1). The IC<sub>50</sub> for enisamium chloride in Caco-2 cells was 1.2 mM 126 (~300 µg/ml), which is comparable to the inhibitory effect of enisamium on influenza 127 A virus replication in Caco-2 cells (13). To test if enisamium inhibited SARS-CoV-2 128 replication in NHBE cells, NHBE cells were incubated with enisamium iodide for 6 129 hours and subsequently infected with SARS-CoV-2. Analysis of the viral RNA levels 130 in infected NHBE cells revealed an IC<sub>50</sub> of 250 µg/ml (Fig. 1D). We obtained 131 comparable results in NHBE cells infected with alpha-coronavirus HCoV NL63 (Fig. 132 1E), implying that enisamium can inhibit coronavirus replication.

133

#### 134 Enisamium and VR17-04 inhibit SARS-CoV-2 nsp12/7/8 activity

Previous experiments showed that enisamium and VR17-04 can inhibit the influenza A virus RNA polymerase *in vitro* (13). To determine if enisamium and its putative metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase, we used a SARS-CoV-2 RNA polymerase *in vitro* assay that involved nsp12 as the RNAdependent RNA polymerase, and nsp7 and nsp8 as processivity factors. We expressed and purified SARS-CoV-2 nsp7, nsp8 and nsp12, and mixed them at a

141 ratio of 2:2:1 to form a nsp12/7/8 complex. Next, we incubated the nsp12/7/8 142 complex with a hairpin template (Fig. 1F) in the presence of 0.5 mM of each 143 nucleotide triphosphate (NTP) and varying concentrations of enisamium or the 144 previously identified enisamium metabolite VR17-04. Enisamium inhibited nsp12/7/8 145 activity at relatively high concentrations, with an  $IC_{50}$  of 26.3 mM (Fig. 1G). By 146 contrast, VR17-04 had an estimated IC<sub>50</sub> of 0.98 mM on the hairpin template (Fig. 147 1G). These  $IC_{50}$  values are within an order of magnitude of those observed for the 148 inhibition of the influenza virus RNA polymerase (13). Moreover, the  $IC_{50}$  value for 149 VR17-04 on SARS-CoV-2 nsp12/7/8 is similar to remdesivir triphosphate in the 150 presence of 0.5 mM NTPs in a comparable assay (14). A 10-fold reduction of the 151 NTP concentration in the assay lowered the VR17-04  $IC_{50}$  value to 0.029 mM (Fig. 152 1G), suggesting that VR17-04 is competing with NTP incorporation. Collectively, 153 these data suggest that RNA synthesis by the SARS-CoV-2 nsp12/7/8 complex is 154 inhibited by enisamium and its metabolite VR17-04 in vitro.

155

Enisamium forms hydrogen bonds with adenine and cytosine in nsp12 and influenza
 polymerase active site

158 Previous studies (13, 15) and our data in Fig. 1A, suggest that enisamium acts 159 through metabolite VR17-04 and inhibits the activity of the influenza A virus and 160 SARS-CoV-2 nsp12 RNA polymerases. However, the mechanism of RNA synthesis 161 inhibition by VR17-04 is not fully understood. We hypothesised that the additional 162 OH-group of VR17-04 could support hydrogen bond formation with adenine and 163 cytosine (Fig. 2A), creating two hydrogen bonds in total, while enisamium would form 164 only one hydrogen bond with these bases. We expected that VR17-04 would not 165 form hydrogen bonds with guanine or uridine (Fig. S2), suggesting that the inhibitory 166 effect of VR17-04 would be dependent on the template sequence.

The CO and OH groups of VR17-04 can adopt *trans* and *eclipsed* conformations that are characterized by three dihedral angles:  $\phi_1$ ,  $\phi_2$  and  $\phi_3$  (Fig. 2B). Dihedral angles  $\phi_1$  and  $\phi_2$  are also present in enisamium, but  $\phi_3$  involves different atoms (Fig. S4). In VR17-04, dihedral angle  $\phi_3$  is ~180° in the *trans* conformation and ~0° in the *eclipsed* conformation (Fig. 2B). Based on quantum chemical calculations, the *eclipsed* conformation has a lower energy than the *trans* transformation (Table S1), and only the *eclipsed* conformation would be compatible

174 with cytosine or adenosine binding (Fig. 2B). To confirm that VR17-04 can adopt the eclipsed conformation in solution, we measured the <sup>1</sup>H NOESY spectrum of VR17-175 176 04 in water and found a correlation between the protons 'HN' and 'H5' that is compatible with a ¢3 value of 0° (Fig. 2C). The chemical shifts of the selected 177 178 protons are reported in Table S2. Additionally, we observed a correlation between 179 the HN and the  $CH_2$ , or the ortho aromatic protons of the Ph group (Fig. 2C). These 180 observations suggest that VR17-04 can adopt a conformation that would be 181 compatible with hydrogen bond formation with cytosine and adenine.

182 To further investigate whether VR17-04 can inhibit the activity of the SARS-183 CoV nsp12 RNA polymerases through base-pair interactions with the template, we 184 docked enisamium or VR17-04 into the SARS-CoV-2 nsp12/7/8 complex bound to 185 template RNA and remdesivir monosphosphate (PDB 7bv2, Fig. 2D). Prior to 186 docking, we removed the remdesivir monosphosphate from the complex, and used 187 in silico mutagenesis to change the uridine in the active site to cytosine or adenine. After selection of the most significant poses, we found that both enisamium and 188 189 VR17-04 can be accommodated in the +1 position of the nucleotide binding pocket (Fig. 2E-G), in a position similar to remdesivir monosphosphate (Fig. 2D). VR17-04 190 191 was specifically coordinated through hydrogen bond interactions with the unpaired 192 cytosine residue of the template RNA. Nsp12 residues K545 and K555 were 193 predicted to preserve the VR17-04 position in the catalytic cavity (Fig. S4). In 194 addition, our modelling suggests that VR17-04 can form a stacking interaction with 195 the -1 base of the nascent strand. By contrast, enisamium docked in the same +1 196 nascent strand position, but only formed one hydrogen bond with the cytosine in the 197 +1 template position (Fig. S4).

198 To estimate the binding stability of enisamium or VR17-04 in the nsp12 active 199 site, we performed molecular dynamics (MD) simulations of enisamium or VR17-04 200 in the nsp12 active site (see Material and Methods for specifics). Our MD simulations 201 predict that VR17-04 favourably binds the unpaired cytosine in the +1 position of 202 nsp12/7/8 complex, maintaining two hydrogen bonds (Watson-Crick base pair) as 203 seen by the preserved hydrogen bonds distances (Fig. 2 E-G) and the coplanarity 204 angle (Fig. 2H, I). By contrast, our simulations predict that enisamium binds less 205 stably to the nsp12/7/8 complex, based on the ~2-fold difference in distance between 206 enisamium and cytosine compared to VR17-04 and cytosine (Fig. 2E, F; Table S3),

and a higher estimated Poisson-Boltzmann free energy for the enisamium binding
(43.6 kcal/mol) compared to VR17-04 binding to either cytosine (-19.8 kcal/mol) or
adenine (-14.8 kcal/mol) (Table S4).

210 To investigate if VR17-04 inhibits the SARS-CoV nsp12/7/8 RNA polymerase 211 complex in a sequence-specific manner, we analysed the extension of a hairpin 212 template containing a cytosine or adenine in the +1 position of the template (Fig. 2J) 213 in the presence or absence of VR17-04. We found that at high VR17-04 214 concentrations, the nsp12/7/8 RNA polymerase complex was prevented from 215 incorporating GTP and UTP (Fig. 2J). When we subsequently moved the cytosine 216 residue to the +2 nt position of the template down and introduced a uridine at the +1 217 position, ATP was incorporated in the presence of VR17-04 but GTP was not (Fig. 218 2K), suggesting that the inhibitory activity of VR17-04 is dependent on the sequence 219 of the template.

220

221 Enisamium Improves COVID-19 Patient Recovery in Interim Analysis of Clinical Trial 222 To investigate if enisamium affects the clinical course of COVID-19 patients, a 223 double-blind, randomized, placebo-controlled phase III clinical study was performed. 224 The COVID-19 diagnosis was based on a body temperature of ≥37.8 °C and 225 laboratory confirmed presence of SARS-CoV-2 RNA by RT-PCR in pharyngeal 226 swabs or sputum. The patient cohorts required either medical care but no 227 supplementary oxygen (Severity Rating (SR) 5; WHO score 3), or medical care and 228 supplementary oxygen (SR 4; WHO score 4) on the day of enrolment and 229 randomization. Randomized COVID-19 patients were treated with either placebo 230 (group A) or enisamium chloride (group B) for 7 days. The chosen primary endpoint 231 of the trial was time-to-recovery, and recovery was defined as an improvement in the 232 SR baseline status by 2 SR score values (e.g., a change from SR 4 to SR 6).

233 In accordance with the study protocol, an interim analysis on all patients in the 234 Intent-to-Treat evaluation set (ITT) was performed for the primary endpoint by an 235 Independent Data Monitoring Committee (IDMC) using a pre-defined Charter. The 236 ITT set for interim analysis included 373 patients of which 296 patients had SR 5 and 237 77 patients had SR 4 on day of randomization (Fig. 3A). The interim analysis showed 238 no difference in time-to-recovery and median time-to-recovery between all placebo-239 and enisamium-treated ITT patients (Fig. 3B) nor in the subgroup of patients with SR 240 5 (Fig 3C). In contrast, analysis of the SR 4 subgroup alone (n = 77) revealed a

241 faster time-to-recovery with the enisamium-treated patients compared to the 242 placebo-treated for the whole period of recovery, starting 7 days after randomization 243 (Fig. 3D). The estimated median time-to-recovery was 13 days for the placebo-244 treated patients and 11 days for the enisamium-treated patients. The mean time-to-245 recovery was 13.9 days for the placebo-treated group and 11.1 days for the 246 enisamium-treated group. The log-rank test showed a significant advantage in 247 recovery time in favour of enisamium treatment at interim stage (P = 0.0259). The 248 maximum time-to-recovery was reached on day 21 for the enisamium-treated group. 249 Not all patients recovered in the placebo-treated group. For these patients, the 250 recovery time was displayed as 29 days (Fig. 3D).

Based on the above findings, the IDMC recommended to stop recruitment of patients requiring only medical care but no oxygen (SR 5; WHO score 3) and to continue the study with COVID-19 patients requiring supplementary oxygen in addition to standard medical care (SR 4; WHO score 4).

- 255
- 256

## 257 Discussion

258 The rapid global spread of SARS-CoV-2 necessitates development of effective 259 therapeutic interventions, and the most promising short-term strategy is to repurpose 260 existing drugs. In this study we showed that enisamium, which is approved for use 261 against influenza in 11 countries, can inhibit SARS-CoV-2 RNA synthesis (Fig. 1). 262 Moreover, we showed that enisamium and its metabolite, VR17-04, inhibit the RNA 263 synthesis activity of the SARS-CoV-2 nsp12/7/8 complex (Fig. 1, 2). Molecular 264 dynamics analysis and in vitro activity assays suggest that VR17-04 prevents GTP 265 and UTP incorporation into the nascent RNA chain (2).

266 It was previously reported that enisamium inhibits the influenza A virus RNA 267 polymerase activity in vitro with a relatively high  $IC_{50}$  value of 46.3 mM (13). This 268 inhibition was improved 55-fold by addition of a hydroxyl group in the compound 269 VR17-04 (13). We find that SARS-CoV-2 nsp12/7/8 complex activity is inhibited by 270 enisamium and VR17-04 with similar IC<sub>50</sub> values to the influenza A virus RNA 271 polymerase at similar NTP levels (Fig. 1) (13). Furthermore, the IC<sub>50</sub> value for VR17-272 04 is similar to remdesivir triphosphate in a similar in vitro assay used (14). 273 Remdesivir triphosphate is the active metabolite of remdesivir, which has shown

274 promise in both cell culture and clinical trials as a treatment for SARS-CoV-2 275 infection (16).

276 Our docking and molecular dynamics simulations suggest that VR17-04 can 277 bind a template cytosine or adenine base in the active site of the SARS-CoV-2 RNA 278 polymerase. This hypothesis is supported by our NOE experiments performed in 279 water, which indicate that VR17-04 can adopt an *eclipsed* conformation in solution. 280 Only the *eclipsed* conformation is compatible with the sequence-specific inhibition 281 we observed in our in vitro polymerase reactions. We cannot fully exclude the 282 possibility that VR17-04 can also bind bases in the nascent RNA strand. However, 283 we think that this alternative explanation does not adequately explain our data.

284 We observed that the inhibitory effect of enisamium was more pronounced in 285 NHBE cells than in Caco-2 cells, which is in line with previous influenza A virus 286 experiments (13, 15) and suggest that enisamium is more readily metabolised into 287 VR17-04 in primary bronchial epithelial cells compared to adenocarcinoma cells. 288 Interestingly, the interim phase III clinical trial results that we disclose here reveal a 289 faster improved recovery in COVID-19 patients needing supplementary oxygen, 290 strongly suggesting that our in vitro data are well-aligned with the data from the 291 clinical trial. We cannot exclude that enisamium or its metabolite has effects beyond 292 RNA polymerase inhibition and that these additional effects contribute to the COVID-293 19 patient recovery.

294 Overall, our results strongly suggest that enisamium metabolite VR17-04 295 inhibits RNA synthesis by the SARS-CoV-2 nsp12/7/8 complex. Together with the 296 interim phase III clinical trial findings that enisamium improved the recovery of 297 COVID-19 needing supplementary oxygen (SR 4) by more than 2 days, our 298 observations raise the possibility that enisamium could be used a viable therapeutic 299 option against SARS-CoV-2 infection. Moreover, unlike remdesivir, enisamium does 300 not require intravenous administration, which would be advantages for its use 301 outside of a hospital setting. Together with observations that enisamium can inhibit 302 other RNA virus infections, and DNA virus infections (13, 15, 17), these results here 303 suggest that it can act as broad-spectrum polymerase inhibitor.

304305

## 306 Materials and Methods

## 307 SARS-CoV-2 infections

308 Confluent layers of Caco-2 cells in 96-well plates were treated with serial dilutions of 309 FAV00A or FAV00B 6 hours prior to infection. The cells were infected with SARS-310 CoV-2 at multiplicity of infection 0.01 for 1 h, and compound reapplied following virus 311 removal. At 48h post infection, the cytopathic effect was recorded by examination of 312 infected cultures by light microscopy and supernatant collected to quantify virus RNA 313 RT-qPCR as described previously, using nsp12-specific primers 5'by 314 GTGARATGGTCATGTGTGGCGG-3' 5'and 315 CARATGTTAAASACACTATTAGCATA-3' (18-20). Cells were fixed with 316 acetone/methanol (40:60) and immunostained using a SARS-CoV-2 nucleoprotein 317 monoclonal antibody (1:500, Sinobiological, Cat #40143-R019-100ul). Staining was 318 detected using a peroxidase conjugated anti-rabbit secondary antibody (1:1000, 319 Dianova) and the addition of AEC substrate.

320

## 321 HCoV-NL63 NHBE infections

322 MatTek's EpiAirway System (MatTek; Ashland, MA) consisted of differentiated 323 NHBE cells that were cultured to form a multilayered, highly differentiated model that 324 closely resembles the epithelial tissue of the respiratory tract. The cells from a single 325 donor (No. 9831) were used for assay consistency. The apical surface of the cells 326 was exposed to a humidified 95% air/ 5% CO2 environment. The basolateral 327 medium was changed, and the mucin layer was washed every 24-48 hours. NHBE 328 cells were inoculated via the exposure of the apical side to HCoV-NL63. After 1 hour 329 of incubation with virus in a water-jacketed 37°C incubator with a 5% CO2 supply, 330 the viral inoculum was removed from the cells. The apical side of the cells was 331 washed once prior to infection. After viral inoculation, enisamium chloride or control 332 media were added to the apical side of the cells and the basal media compartment 333 and incubated with the cells for 1 hour. After a 1-hour incubation, the drug containing 334 media was removed from apical and basal chambers. Growth medium alone or 335 growth medium with enisamium chloride were added to the bottom chamber, and 336 cells were incubated for 48 hours. At the termination of the experiments, cells were 337 washed twice, then 1 ml Trizol (Invitrogen) was added to each well for RNA isolation. 338 Total RNA was isolated from cells using Trizol per the manufacturer's instruction. 339 Two-step RT-qPCR was performed using HCoV-NL63 N gene-specific primers/probe 340 (forward primer: 5'-TGGTGTTGTTTGGGTTGCTA-3', reverse primer5'-341 5'-GCTCTGGAGGCAAAGCAATA-3', double-quenched probe:

FAM/CGCAAACGT/ZEN/AATCAGAAACCTTTGGA/IABKFQ-3'), GAPDH was analysed
at the same time with GAPDH-specific primers (5'- GTTCGACAGTCAGCCGCATC3' and 5'- AGTTAAAAGCAGCCCTGGTGA-3') by RT-qPCR and served as a
reference gene for normalization.

346

## 347 SARS-CoV-2 nsp12/7/8 in vitro activity assays

348 Plasmids expressing nsp7, nsp8 and nsp12 were kindly provided by Dr Ervin Fodor 349 (University of Oxford). Nsp7, nsp8 and nsp12 were purified as described previously 350 (14) and mixed at a molar ratio of 2:2:1 to form active nsp12/7/8 complex. For activity 351 50 nM (5'assays, hairpin template 352 CGUAGGAGAAUGACAAAAUUUUGUCAUUCUCC-3'), or a variation of this 353 template (see figures), was incubated with 1  $\mu$ M nsp12/7/8 complex for 30 mins at 30 354 °C, in reaction buffer containing 5 mM MgCl<sub>2</sub>, 20 mM Hepes pH 8.0, 0.5 mM ATP, 355 0.5 mM UTP, 0.5 mM GTP, 0.5 mM CTP, 0.05% NP-40, 5% glycerol, 50 mM NaCl, 1 356 U RNasin (Promega) and 1 mM DTT. Hairpin templates were based on the 3' 357 terminal sequence of the SARS-CoV-2 genome and reference (3). Reactions were 358 stopped by addition of 80% formamide and 10 mM EDTA, followed by heating to 95 359 °C for 3 min. Reaction products were resolved by 20 % denaturing PAGE with 7M 360 urea, and visualised by phosphorimaging on a Typhoon FLA 7000 (GE Healthcare) 361 scanner. Data were analysed using ImageJ and Prism 9 (GraphPad). Enisamium iodide (Farmak) or VR17-04 (Farmak) were dissolved in DMSO to a stock 362 363 concentration of 250 and 125 mg/ml, respectively. Dilutions were made in DMSO.

364

## 365 NOE NMR spectra measurement

The VR17-04 (2 mg) was dissolved in 0.6 ml D2O/water solution (5% D2O). NMR experiments were performed at 500MHz at 277 K. For NOESY experiments (noesygpph) 128 transients were collected for each free-induction decay, using a mixing time of 300 ms and 20 sec of relaxation delay. NOESY experiment (matrix 1024 · 320 points) was zero-filled to 2K · 2K before Fourier transformation. Measurements were taken on a Bruker 500 HD NMR spectrometer equipped with a 5 mm BB probe.

373

#### 374 **Conformational characterization and geometry optimization**

The VR17-04 and enisamium conformational characterization and geometry optimization was done using the quantum chemical approach DFT B3LYP/6-31G\*. The lowest energy conformation of VR17-04 ( $\phi_3$  *eclipsed*) and enisamium were selected for further docking and for partial charge estimation (Table S1).

379

#### 380 Molecular docking

381 The docking simulation was performed using Autodock 4.2 software (21). The 382 geometry of the ligands was previously optimized by DFT B3LYP/6-31G\*. The geometry of the receptor RdRp was extracted from the PDB 7bv2 (22). The catalytic 383 384 site of the nsp12/7/8 complex include the template RNA strand, the nascent strand RNA, the pyrophosphate mojety  $[O_3P-O-PO_3]^{-4}$  (pyr) and two Mg<sup>+2</sup> ions, whose 385 positions were included in 7BV2. The two Zn<sup>+2</sup> ions that were co-crystallized in 7BV2 386 387 were also included in the models. The co-crystallized inhibitor remdesivir was 388 removed from the complex, while its position and the contacts with the template RNA 389 trough the unpaired uracil base in the +1 position were used to guide the molecular 390 docking. The unpaired uracil base was subsequently mutated in cytosine (Cyt) or 391 adenine (Ade) in Pymol 2.3.4 (Schrodinger LLC), generating two different 392 complexes, identified as nsp12/7/8(Cyt) and nsp12/7/8(Ade) respectively. Next, 393 Gasteiger charges were calculated for both ligands (VR17-04, enisamium) and the 394 receptor complexes, and used as parameters of the docking simulation (23). In the 395 docking simulation VR17-04 and enisamium were described by five and four 396 rotational degrees of freedom, respectively. The docking gridbox was built by 397 orthogonal hedges of length between 60 to 80 points. The gridbox centre was set to 398 the NH<sub>2</sub>- group of the target cytosine or adenine residues of the template RNA 399 strand, respectively, and further set-up to fit the space between the R555 and K545, 400 and the uracil of the nascent RNA strand. The docking runs used the default Genetic 401 Algorithm search, with parameters: number of GA runs, population size, max number 402 of energy evaluation, and max number of generations set as 100, 2000, 2.5 10', 403 270.000. At each run the docking solutions were clustered using a tolerance RMSD 404 = 2.0 Å. Three different docking simulations were run: VR17-04 and enisamium were 405 docked on to nsp12/7/8(Cyt), while, for comparison, VR17-04 was further docked on 406 nsp12/7/8(Ade). The docking solutions were selected based on two criteria. The first 407 criterium was the possibility to form a Watson-Crick base-pair interaction between

VR17-04 (or enisamium) and the unpaired cytosine or adenine. The second criterium was based on the possibility to figure out interferences of the ligand with the catalytic mechanism, for example by interaction with key residues of the nsp12/7/8 complex. The selected poses were further ranked by preliminary MD simulation (approximately 20 ns) in explicit solvent, to predict the stability of the interaction, and to estimate the Poisson-Boltzmann free energy of binding, this last property was used to obtain a final selection and ranking of the poses.

415

#### 416 Molecular dynamic simulation

417 Explicit solvent MD simulation were run using NAMD 2.12 (24) software, applying the 418 Amber force field (ff14SB) (25). The TIP3P (26) water solvent model was used. The 419 t-leap application of the Ambertools 14.0 package (25) was applied to generate the 420 topology, the parameters, and the coordinate files of the macromolecular complex 421 simulated. The coordinates of the macromolecular elements of the nsp12/7/8 422 complex: nsp12, nsp8, nsp7, pyr, template RNA, nascent strand RNA, were 423 extracted from the PDB 7bv2. The geometries of the VR17-04, enisamium (before 424 docking) and pyr were optimized using the quantum chemical approach DFT 425 B3LYP/6-31G<sup>\*</sup>; the corresponding partial charges were estimated fitting the 426 electrostatic potential that was calculated at level of theory B3LYP/6-31G\*/RHF/6-427 31G\*. This procedure is in accord to the standard required by the Amber force field. 428 The quantum chemistry software GAMESS (27) was used for this stage. The Amber 429 atomtypes (parm10.dat) were selected for VR17-04, enisamium and pyr 430 (antechamber application, Ambertools 14.0). Three macromolecular complexes 431 indicated as VR1704-nsp12/7/8(Cyt), enisamium-nsp12/7/8(Cyt), and VR1704-432 nsp12/7/8(Ade), were solvated by a 15 Å wide layer of TIP3P water molecules in 433 each X, Y, Z direction; the orthogonal simulation box was built with hedges of 434 approximate length 116, 116, 127 Å. The non-bond electrostatic and dispersive 435 interactions were described by the standard cut-off technique (12.0 A). Before 436 running MD simulation, each simulation cell box was energy minimized running 200 437 K steps of the default energy minimized algorithm, as implemented in NAMD. The 438 MD simulations were run fixing the number of particle (N), the absolute temperature 439 (T), and the pressure (P) applied to the cell hedges. The absolute temperature was 440 300 K and maintained with a Lowe-Andersen thermostat, while the pressure on the 441 cell box hedges was set as P = 1.01325 bar and preserved by the Nosé-Hoover-

442 Langevin piston algorithm. The first MD simulation stage was run to adjust the 443 simulation cell box density, allowing the relaxation of all the inter-molecule distances, 444 i.e., the solute-solute, solute-solvent, and solvent-solvent distances. The cell density 445 equilibration stage was run restraining the atoms of the solute to their initial position 446 (energy minimized geometry of the complex) applying a harmonic restraint. In this 447 stage of cell density equilibration, the water molecules were left free to move. The 448 harmonic restraint constant value was set initially as 1 Kcal mol<sup>-1</sup> for each atom of the solute, and progressively reduced at 0.5 and 0.2 Kcal mol<sup>-1</sup>. The cell density 449 450 equilibration stage was monitored plotting the cell volume ( $\dot{A}^3$ ) vs time (ns), until the 451 cell volume fluctuations level-off to a horizontal axis that corresponds to the average 452 final volume of the cell. This stage required between 20 to 50 ns approximately and 453 was further checked by the formation of a thin water shell that surround the face of 454 the inhibitor molecule that is exposed to the empty catalytic cavity of the nsp12/7/8 455 complex. In the second stage of the MD simulation, the harmonic restraint was 456 removed, and the inhibitor-nsp12/7/8 complex was allowed to equilibrate in the 457 geometry and the relative position of their elements: inhibitor, template RNA, nascent strand RNA, pyr, Mg<sup>+2</sup>, and Zn<sup>+2</sup>. To monitor the equilibration of position and 458 459 orientation that VR17-04 (or enisamium) presents in the +1 position of the catalytic 460 cavity, the distances between the carbonyl oxygen of VR17-04 and the hydrogen 461 (NH<sub>2</sub>-) of cytosine (or adenine), and between the hydroxyl group of VR17-04 and the 462 nearby lone pair of cytosine nitrogen (or adenine), were plotted vs simulation time. 463 These distances provide a direct indication of the stability of the Watson-Crick base 464 pair interaction that hold the inhibitor and the target base. The orientation of the 465 VR17-04 in the catalytic site of the nsp12 were also monitored by the improper 466 dihedral angle  $\phi$  defined by the following atoms (bold) CO-NH<sub>2</sub>-N-OH, in which CO 467 and **O**H belong to VR17-04, while the remaining  $NH_2$  and N belong to the opposite 468 cytosine (or adenine). Alternatively, the enisamium-cytosine pair require the following 469 atoms CO-NH<sub>2</sub>-N-CH to define  $\phi$ , in this case CO and CH belong to enisamium, 470 while **N**H<sub>2</sub> and **N** belong to the opposite cytosine. In fact, values of this angle around 471 '0' indicate that the 'base pair' contact between VR1704 the cytosine (or adenine) is 472 coplanar, a geometric condition favouring the Watson-Crick 'base-pair' interaction 473 between VR17-04 and the base. VMD 1.9.3 (28) was used for the MD simulation 474 trajectory visualization and image creation.

medRxiv preprint doi: https://doi.org/10.1101/201.01.05.21249237; this version posted January 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

In a system that evolve in accord to the complex formation reaction (29).

 477
 In a system that evolve in accord to the complex formation reaction (29).

 478
 
$$L + R = L - R$$

 479
 (eq. 1)

 480
 The free energy change is calculated knowing only the initial and final state of the system:

 482
  $\Delta G^{Bind} = G(L - R) - G(L) - G(R)$ 

 483
 (eq. 2)

 484
 The free energy decomposed in the following terms:

 485
  $G = \langle E_{MM} \rangle + \langle G_{sol} \rangle + \langle G_{noPol} \rangle - T \langle S_{MM} \rangle$ 
 (eq. 3)

 486
 The free energy change is then conveniently split:
  $\Delta G^{Bind} + \Delta S_{MM}$ 
 (eq. 4)

 487
 Defended =  $\Delta G_{F_{a}}^{Dind} + \Delta S_{MM}$ 
 (eq. 4)
 In eq. 3 the  $E_{MM}$  correspond to the potential energy of the system, as described by

 489
 the force-field;  $G_{sol}$  is the polar solvation energy, estimated by the Poisson-
 Boltzmann equation (30);  $G_{napol}$  is the non-polar solvation energy, estimated by the

 491
 solvent-accessible surface area, a method included in the MMPBSA.  $T$  is the

 492
 absolute equilibrium temperature, while  $S_{MM}$  is the molecular entropy of the system.

 493
 the genergy of binding  $\Delta G_{FB}^{Bind}$  (see eq. 4). To estimate

 494
 the absolute value of the free energy of binding  $\Delta G_{FB}$ 

502 503

#### 504 **Patients**

experiment.

505 For this prospective, multi-centre, randomized, double-blind, placebo-controlled, 506 parallel-group phase III clinical trial, male and female hospitalized patients ≥ 18 507 years with moderate severity of COVID-19 infection were eligible for participation.

16

2), or

could

The diagnosis of COVID-19 was based on body temperatures of  $\geq$  37.8 °C and laboratory confirmed RT-PCR SARS-CoV-2 test from pharyngeal swabs or sputum. According to intent-to-treat (ITT) definition and the actual recruitment status, 373 patients from 15 Ukrainian hospitals could be included into the interim analysis.

The study was conducted in accordance with the Declaration of Helsinki, ICH-GCP and the national laws and regulations in Ukraine. All patients singed an informed consent prior to study participation. The study was approved by the Ethics Commission of the Regional Clinical Hospital of Ivano-Frankivsk Regional Council on 12.05.2020. The registration number of the study in ClinicalTrials.gov is NCT04682873.

518

## 519 Treatment

Patients were randomized at a 1:1 ratio to receive either 500 mg enisamium chloride or matching placebo 4 times daily every 6 h for 7 full days. Supporting treatment could be given at the investigator's discretion. All patients treated with either placebo or enisamium, having a laboratory-confirmed SARS-CoV-2 at randomization and providing any valid efficacy data after initiation of treatment were included in the Intent-to-Treat evaluation set (ITT).

526

#### 527 Data Collection

528 Baseline clinical data of the patients were recorded in the electronic case report 529 forms including demographics, medical history, previous and ongoing medication, 530 body height and weight and results of physical examination. During the study up to 531 day 29 or until discharge, symptom severity rating, vital signs, assessment of 532 COVID-19 symptoms, safety lab results, concomitant medication and adverse events 533 were recorded. The patient's and investigator's judgment on safety and efficacy were 534 collected independently. RT-PCR tests on SARS-CoV-2 at defined intervals and at 535 the discretion of the investigator were carried out.

536

## 537 Primary Outcome

The primary outcome was measured as the time from the day of randomization (day 1) to an improvement of at least two score points (from the status at randomization) on the severity rating (SR) scale in days. The SR scale (WHO scale) is defined as 1 (8) - Death; 2 (7, 6) - Hospitalized, on invasive mechanical ventilation or

542 extracorporeal membrane oxygenation; 3 (5) - Hospitalized, on non-invasive 543 ventilation or high flow oxygen; 4 (5) - Hospitalized, requiring supplemental oxygen; 544 5 (3) - Hospitalized, not requiring supplemental oxygen – requiring ongoing medical 545 care; 6 (-) - Hospitalized, not requiring supplemental oxygen - no longer requires 546 ongoing medical care; 7 (2) - Not hospitalized, limitation on activities and/or requiring 547 home oxygen; 8 (1) - Not hospitalized, no limitations on activities. Safety of 548 enisamium iodide will be analysed based on the incidence of adverse events, vital 549 signs, judgement of global tolerability on day of hospital discharge (separately by 550 patient and investigator) and laboratory data when the study is completed.

551

## 552 Statistical Analysis of Interim Data.

553 The unblinded interim analysis was carried out by an Independent Data Monitoring 554 Committee based on a pre-specified Charter. At this stage, the primary outcome was 555 pre-planned to be tested by using the two-sided log-rank test stratified by centre. 556 Because of the low patient number in some centres the stratification was omitted for 557 gaining primary interim results. The primary outcome was defined as an 558 improvement from baseline of at least two SR points and was evaluated for all ITT 559 patients at the interim stage as well as for subgroups with baseline score of SR 4 560 and 5 separately. The interim analysis used the promising zone approach according 561 to (31) that was implemented according to (32). For this method no adjustment of the 562 type-I error rate is needed.

563

## 564 Acknowledgments

565 The authors would like to thank Dr. Juergen Richt (Kansas State University, 566 Manhattan, KS, US) for comments and advice, and Dr Ervin Fodor, Dr Jonathan 567 Grimes, Alexander Walker, Dr Haitian Fan and Dr Jeremy Keown (University of 568 Oxford, Oxford, UK) for expression constructs and sharing preliminary data.

569

## 570 **Funding**

- 571 A.J.W.t.V is supported by joint Wellcome Trust and Royal Society grant
- 572 206579/Z/17/Z and the National Institutes of Health grant R21AI147172. Part of this
- 573 research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.
- 574
- 575 **Conflict of interest**

576 V.M. and A.G. are employees of Farmak Public Joint Stock Company, Kiev, Ukraine.

- 577 Part of this research was funded by Farmak Public Joint Stock Company, Kiev,
- 578 Ukraine.
- 579
- 580

## 581 **References**

- 5821.T. P. Sheahan *et al.*, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in583human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med58410.1126/scitranslmed.abb5883 (2020).
- 5852.R. M. Cox, J. D. Wolf, R. K. Plemper, Therapeutically administered ribonucleoside analogue586MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol58710.1038/s41564-020-00835-2 (2020).
- 5883.A. Shannon *et al.*, Rapid incorporation of Favipiravir by the fast and permissive viral RNA589polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun 11, 4682590(2020).
- 591 4. D. H. Goldhill *et al.*, The mechanism of resistance to favipiravir in influenza. *Proc Natl Acad* 592 *Sci U S A* **115**, 11613-11618 (2018).
- 5935.E. Hartenian *et al.*, The molecular virology of coronaviruses. J Biol Chem 295, 12910-12934594(2020).
- 5956.V. Coronaviridae Study Group of the International Committee on Taxonomy of, The species596Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it597SARS-CoV-2. Nat Microbiol 5, 536-544 (2020).
- 5987.L. Subissi *et al.*, SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes599as antiviral targets. Antiviral Res 101, 122-130 (2014).
- 6008.A. J. te Velthuis, J. J. Arnold, C. E. Cameron, S. H. van den Worm, E. J. Snijder, The RNA601polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res 38,602203-214 (2010).
- 603 9. L. Subissi *et al.*, One severe acute respiratory syndrome coronavirus protein complex
  604 integrates processive RNA polymerase and exonuclease activities. *Proc Natl Acad Sci U S A*605 111, E3900-3909 (2014).
- 60610.L. Yan *et al.*, Architecture of a SARS-CoV-2 mini replication and transcription complex. Nat607Commun 11, 5874 (2020).
- 60811.H. S. Hillen *et al.*, Structure of replicating SARS-CoV-2 polymerase. *Nature* 584, 154-156609(2020).
- 61012.J. Chen *et al.,* Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2611Replication-Transcription Complex. Cell **182**, 1560-1573 e1513 (2020).
- 61213.T. G. Zubkova *et al.*, Enisamium reduces influenza virus shedding and improves patient613recovery by inhibiting viral RNA polymerase activity. *MedRxiv* (2020).
- 61414.A. P. Walker *et al.*, Enisamium is a small molecule inhibitor of the influenza A virus and SARS-615CoV-2 RNA polymerases. *bioRxiv* 10.1101/2020.04.21.053017 (2020).
- 616 15. D. Boltz *et al.*, Activity of enisamium, an isonicotinic acid derivative, against influenza viruses
  617 in differentiated normal human bronchial epithelial cells. *Antivir Chem Chemother* 26,
  618 2040206618811416 (2018).
- 619
   16.
   J. H. Beigel *et al.*, Remdesivir for the Treatment of Covid-19 Final Report. *N Engl J Med* 383,

   620
   1813-1826 (2020).
- K. V. Zurbaev, A. V. Slita, E. O. Sinegubova, A. A. Muryleva, I. N. Lavrentieva, Anti-viral
  activity of enisamium iodide against viruses of influenza and ARVI's on different cell lines. *Therapeutic Archive* 92, 45-50 (2020).
- 62418.D. Bojkova *et al.*, Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.625Nature 583, 469-472 (2020).
- 626 19. D. Bojkova *et al.*, Aprotinin Inhibits SARS-CoV-2 Replication. *Cells* **9** (2020).

onegativity a rapid	
	t Chem <b>26</b> , 1781-1802
ns. <i>J Comput Chem <b>26</b>,</i> 1668-	
	Comparison of 26-935 (1983).
System. J. Comput.	
	. Mol. Graphics <b>14</b> ,
ies predicted with force field. <i>J. Med.</i>	
	t
	. Am. Chem. Soc.
bei	
pei	
pei	



659

Figure 1. Enisamium inhibits SARS-CoV-2 infection and replication in vitro. (A) 660 Chemical structures of FAV00A and VR17-04. The chemical structure of FAV00B is 661 identical to FAV00A except that chloride ions are present instead of iodide. (B) 662 Inhibition of SARS-CoV-2 N expression in Caco-2 cells by enisamium chloride. (C) 663 664 Inhibition of SARS-CoV-2 cytopathic effect in Caco-2 cells by enisamium iodide and chloride. (D) Quantification of SARS-CoV-2 RNA genome levels in NHBE cells 665 666 infected with SARS-CoV-2 after treatment with enisamium iodide. (E) Quantification of HCoV-NL63 N mRNA levels in NHBE cells infected with HCoV-NL63 after 667 668 treatment with enisamium chloride. (F) Inhibition of the SARS-CoV-2 nsp12/7/8 RNA 669 polymerase complex by VR17-04 on a hairpin template. A mutant containing a double amino acid substitution in the nsp12 active site (SDD=>SAA) was used as 670 671 negative control. DMSO was used as solvent control. (G) Quantification of SARS-672 CoV-2 nsp12/7/8 RNA polymerase complex inhibition by enisamium or VR17-04 on 673 a hairpin template. For VR17-04 two nucleotide triphosphate concentrations were 674 used. Polymerase activity was plotted against drug concentration and dose-response 675 curves were fit to the data. Quantification is from n=3 independently prepared reactions using the same nsp12/7/8 protein preparation. Error bars represent 676 standard deviation. 677



678 Figure 2. Enisamium metabolite VR17-04. (A) Schematic of putative hydrogen 679 680 bond formation between cytosine and adenine bases with VR17-04. (B) Schematic of the trans and eclipsed conformations of VR17-04. (C) 2D-NOESY and 1H proton 681 682 (above) spectra of VR17-04 acquired at 277 K in water. The NOE correlation between the HN and H5' proton is highlighted with a dashed line. (D) Structure of the 683 684 SARS-CoV-2 nsp12/7/8 complex bound to RNA and remdesivir monophosphate. Rendering based on PDB 7bv2. (E) Model (top) and MD simulation (bottom) of 685 686 VR17-04 binding to cytosine in nsp12 active site. (F) Model (top) and MD simulation (bottom) of enisamium binding to cytosine in nsp12 active site. (G) Model (top) and 687 688 MD simulation (bottom) of VR17-04 binding to adenine in nsp12 active site. (H) MD 689 simulation of dihedral angle of VR17-04 or enisamium binding to cytosine in nsp12 690 active site. (I) MD simulation of dihedral angle of VR17-04 binding to cytosine or 691 adenine in nsp12 active site (J) Effect of VR17-04 on SARS-CoV-2 nsp12/7/8 activity 692 on two different hairpin templates in the presence of GTP (left) or UTP (right). In the 693 presence of wildtype nsp12/7/8 and GTP or UTP, the radiolabelled primer was 694 extended by 1 nt. (K) Effect of VR17-04 on SARS-CoV-2 nsp12/7/8 primer extension 695 activity. A mutant containing a double amino acid substitution in the nsp12 active site (SDD=>SAA) was used as negative control. ATP and GTP were added to the 696 697 reaction to allow extension of the template by 2 nt.



698 Days to improvement
699 Figure 3. Enisamium improves recovery of COVID-19 patients requiring 699 supplementary oxygen. (A) Schematic of patient recruitment, randomization and 701 treatment. (B) Kaplan-Meier plot of the percentage improvement observed in all 702 COVID-19 patients, (C) RS 5 COVID-19 patients (medical care with no oxygen 703 support), and (D) RS 4 COVID-19 patients (medical care with non-invasive oxygen 704 support).